Azaindole-Derivatives As Factor Xa Inhibitors

Abstract

Indazole-derivatives as factor Xa inhibitors The present invention relates to compounds of the formula I wherein R 0 , R 1 , R 2 , R 3 , Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

1 . A compound of the formula I, 
     
       
         
         
             
             
         
       
     
     wherein
 R 0  is
 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R8, 
 2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl selected from the group consisting of benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl and 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or 
 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8; 
 
 R8 is
 1) halogen, 
 2) —NO 2 , 
 3) —CN, 
 4) —C(O)—NH 2 , 
 5) —OH, 
 6) —NH 2 , 
 7) —O—CF 3    
 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by halogen or —O—(C 1 -C 8 )-alkyl, 
 9) —(C 1 -C 8 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH 2 , —OH or methoxy, 
 10) —O—(C 1 -C 8 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH 2 , —OH or methoxy, 
 11) —SO 2 —CH 3  or 
 12) —SO 2 —CF 3 , 
 provided that when R 0  is a monocyclic or bicyclic 6- to 14-membered aryl, then R8 is least one of the substituent of the aryl is halogen, —C(O)—NH 2  or —O—(C 1 -C 8 )-alkyl; 
 
 the substructure 
 
     
       
         
         
             
             
         
       
       in formula I is a 4- to 8 membered saturated, partially unsaturated or aromatic cyclic group containing zero, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by R3, or substituted 1 or 2 times by ═O, provided that said cyclic group is not a phenyl residue; 
       Q is a direct bond, —(C 0 -C 2 )-alkylene-C(O)—NR 10 —, —NR 10 —C(O)—NR 10 —, —NR 10 —C(O)—, —SO 2 —, —(C 1 -C 6 )-allylene, —(CH 2 ) m —NR 10 —C(O)—NR 10 —(CH 2 ) n —, —(CH 2 ) m —NR 10 —C(O)—(CH 2 ) n —, —(CH 2 ) m —S—(CH 2 ) n —, —(CH 2 ) m —C(O)—(CH 2 ) n —, —(CH 2 ) m —SO 2 —NR 10 —(CH 2 ) n —, —(CH 2 ) m —NR 10 —SO 2 —(CH 2 ) n —, —(CH 2 ) m —NR 0 —SO 2 —NR 10 —(CH 2 ) n —, —(CH 2 ) m —CH(OH)—(CH 2 ) n —, —(CH 2 ) m —O—C(O)—NR 10 —(CH 2 ) n —, —(C 2 -C 3 )-alkylene-O—(C 0 -C 3 )-alkylene-, —(C 2 -C 3 )-alkylene-S(O)—, —(C 2 -C 3 )-alkylene-S(O) 2 —, —(CH 2 ) m —NR 10 —C(O)—O—(CH 2 ) n —, —(C 2 -C 3 )-alkylene-S(O) 2 —NH—(R 10 )—, —(C 2 -C 3 )-alkylene-N(R 10 )- or —(C 0 -C 3 )-alkylene-C(O)—O—(CH 2 ) m —, 
       wherein —(CH 2 ) m — or —(CH 2 ) n — are alkylene that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, —NH 2  or —OH, or —(C 3 -C 6 )-cycloalkylene, that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, —NH 2  or —OH; 
       R 1  is
 hydrogen, —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or substituted one to three times by R13, —(C 1 -C 3 )-alkylene-C(O)—NH—R 0 , —(C 1 -C 3 )-alkylene-C(O)—O—R 15 , a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by R 8 ; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, 
 —(C 1 -C 3 )-perfluoroalkylene, —(C 1 -C 3 )-allylene-S(O)—(C 1 -C 4 )-alkyl, —(C 1 -C 3 )-alkylene-S(O) 2 —(C 1 -C 3 )-allyl, —(C 1 -C 3 )-alkylene-S(O) 2 —N(R 4′ )—R 5′ , —(C 1 -C 3 )-alkylene-O—(C 1 -C 4 )-allyl, —(C 0 -C 3 )-allylene-(C 3 -C 8 )-cycloalkyl, or —(C 0 -C 3 )-alkylene-het, wherein the het is a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and is unsubstituted or 
 mono-, di- or trisubstituted independently of one another by R14, 
 
       R 4′  and R 5′  are independent of one another are identical or different and are hydrogen atom or —(C 1 -C 4 )-alkyl, 
       R 2  is a direct bond or —(C 1 -C 4 )-alkylene, or 
       R 1  and R 3  together with the atoms to which they are bonded form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 
       R 1 —N—R 2 —V form a 4- to 7-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; 
       R14 is halogen, —OH, ═O, —(C 1 -C 8 )-alkyl, —(C 1 -C 4 )-alkoxy, —NO 2 , —C(O)—OH, —CN, —NH 2 , —C(O)—O—(C 1 -C 4 )-alkyl, —(C 0 -C 8 )-alkyl-SO 2 —(C 1 -C 4 )-alkyl, —(C 0 -C 8 )-alkyl-SO 2 —(C 1 -C 3 )-perfluoroalkyl, —(C 0 -C 8 )-alkyl-SO 2 —N(R 18 )—R 21 , —C(O)—NH—(C 1 -C 8 )-allyl, —C(O)—N—[(C 1 -C 8 )-alkyl] 2 , —NR 18 —C(O)—NH—(C 1 -C 8 )-alkyl, —C(O)—NH 2 , —S—R 18 , or —NR 18 —C(O)—NH—[(C 1 -C 8 )-alkyl] 2 ,
 wherein R 18  and R 21  are independently from each other hydrogen, —(C 1 -C 3 )-perfluoroalkyl or —(C 1 -C 6 )-alkyl; 
 
       V is
 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, 
 2) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 
 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; 
 
       G is
 a direct bond, —(CH 2 ) m —NR 10 —SO 2 —NR 10 —(CH 2 ) n —, —(CH 2 ) m —CH(OH)—(CH 2 ) n —, —(CH 2 ) m —, —(CH 2 ) m —O—(CH 2 ) n —, —(CH 2 ) m —C(O)—NR 10 —(CH 2 ) n —, —(CH 2 )—SO 2 —(CH 2 ) n —, —(CH 2 ) m —NR 10 —C(O)—NR 10 —(CH 2 ) n —, —(CH 2 ) m —NR 10 —C(O)—(CH 2 ) n —, —(CH 2 ) m —C(O)—(CH 2 ) n —, —(CH 2 )—S—(CH 2 ) n —, —(CH 2 ) m —SO 2 —NR 10 —(CH 2 ) n —, —(CH 2 ) m —NR 10 —SO 2 —(CH 2 ) n —, —(CH 2 ) m —NR 10 , —(CH 2 ) m —O—C(O)—NR 10 —(CH 2 ) n — or —(CH 2 ) m —NR 10 —C(O)—O—(CH 2 ) n —; 
 
       n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6; 
       M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; 
       R3 is
 1) hydrogen, 
 2) halogen, 
 3) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 4) —(C 1 -C 3 )-perfluoroalkyl, 
 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 6) —(C 0 -C 4 )-alkylene-O—R 19 , 
 7) —NO 2 , 
 8) —CN, 
 9) —SO s —R 11 , wherein s is 1 or 2, 
 10) —SO t —N(R 11 )—R 12 , wherein t is 1 or 2, 
 11) —(C 0 -C 4 )-alkylene-C(O)—R 11 , 
 12) —(C 0 -C 4 )-allylene-C(O)—O—R 11 , 
 13) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 12 , 
 14) —(C 0 -C 4 )-alkylene-N(R 11 )—R 12 , 
 15) —NR 10 —SO 2 —R 10 , 
 16) —S—R 10 , 
 17) —(C 0 -C 2 )alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—(C 1 -C 4 )-alkyl, 
 18) —C(O)—O—C(R15,R16)-O—C(O)—R17, 
 19) —(C 0 -C 2 )allylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—O—(C 1 -C 6 )-allyl, 
 20) —C(O)—O—C(R15,R16)-O—C(O)—O—R17, 
 21) —(C 0 -C 4 )-alkylene-(C 6 -C 14 )-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13, 
 22) —(C 0 -C 4 )-alkylene-(C 4 -C 15 )-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13 
 23) —(C 0 -C 4 )-alkylene-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 24) —(C 0 -C 4 )-alkylene-het, wherein the het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 25) —(C 0 -C 4 )-alkylene-O—CH 2 —(C 1 -C 3 )-perfluoroalkylene-CH 2 —O—(C 0 -C 4 )-allyl, 
 26) —SO w —N(R 11 )—R 13 , wherein w is 1 or 2, 
 27) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 13    
 28) —(C 0 -C 4 )-allylene-N(R 11 )—R 13 , or 
 29) a residue selected from the group consisting of 
 
     
     
       
         
         
             
             
         
       
       wherein Me is methyl; 
       R 19  is
 a) hydrogen, 
 b) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 c) —CF 3 , or 
 d) —CHF 2 , 
 
       or two —OR19 residues and adjacent atoms through which they are attached may form together a 5- or 6-membered ring, that is unsubstituted or substituted one, two, three or four times by R13; 
       R11 and R12 are independently of one another identical or different and are
 1) hydrogen, 
 2) —(C 1 -C 6 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 3) —(C 0 -C 6 )-alkyl-(C 3 -C 8 )-cycloalkyl, 
 4) —SO t —R 10 , wherein t is 1 or 2, 
 5) —(C 0 -C 6 )-alkyl-(C 6 -C 14 )-aryl, wherein the alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, 
 6) —(C 1 -C 3 )-perfluoroalkyl, 
 7) —O—R 17 , or 
 8) —(C 0 -C 6 )-alkyl-(C 4 -C 15 )-heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or 
 
       R11 and R12 together with the nitrogen atom to which they are bonded form a 4- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; 
       R13 is halogen, —NO 2 , —CN, ═O, —OH, —CF 3 , —C(O)—O—R 10 , —C(O)—N(R 10 )—R 20 , —N(R 10 )—R 20 , —(C 3 -C 8 )-cycloalkyl, —(C 0 -C 3 )-alkylene-O—R 10 , —Si—(CH 3 ) 3 , —N(R 10 )—S(O) u —R 10 , wherein u is 1 or 2, —S—R 10 , —SO r —R 10 , wherein r is 1 or 2, —S(O) v —N(R 10 )—R 20 , wherein v is 1 or 2, —C(O)—R 10 , —(C 1 -C 8 )-allyl, —(C 1 -C 8 )-alkoxy, phenyl, phenyloxy-, —O—CF 3 , —(C 0 -C 4 )-alkyl-C(O)—O—C(R15,R16)-O—C(O)—R17, —(C 1 -C 4 )-alkoxy-phenyl, —(C 0 -C 4 )-alkyl-C(O)—O—C(R15,R16)-O—C(O)—O—R17, —(C 1 -C 3 )-perfluoroalkyl, —O—R15, —NH—C(O)—NH—R 10 , —NH—C(O)—O—R 10  or a residue selected from the group consisting of 
     
     
       
         
         
             
             
         
       
       
          wherein Me is methyl; 
       
       R 10  and R 20  are independently of one another hydrogen, —(C 1 -C 6 )-alkyl, —(C 0 -C 4 )-allyl-OH, —(C 0 -C 4 )-alkyl-O—(C 1 -C 4 )-alkyl or —(C 1 -C 3 )-perfluoroalkyl; 
       R15 and R16 are independently of one another hydrogen, —(C 1 -C 6 )-allyl, or together with the carbon atom to which they are bonded form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R 10′  and 
       R17 is —(C 1 -C 6 )-allyl, —(C 1 -C 6 )-alkyl-OH, —(C 1 -C 6 )-alkyl-O—(C 1 -C 6 )-allyl, —(C 3 -C 8 )-cycloalkyl, —(C 1 -C 6 )-alkyl-O—(C 1 -C 8 )-alkyl-(C 3 -C 8 )-cycloalkyl, or —(C 1 -C 6 )-alkyl-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by —OH, —O—(C 1 -C 4 )-alkyl or R 10 ; 
     
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       2 . The compound according to  claim 1 , wherein
 R 0  as   1) is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or   3) is acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and is additionally substituted by acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;   the substructure D is azetidine, azetine, azocane, azocane-2-one, cyclobutyl, cyclooctane, cyclooctene, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolan, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, [1,4]oxazocane, [1,3]oxazocan-2-one, oxetan, oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thietan, thiocane, thiocane-1,1-dioxide, thiocane-1-oxide, thiocane-2-one, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by R3, or is substituted 1 or 2 times by ═O;   R 1  as a monocyclic or bicyclic 6- to 14-membered aryl is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or
 —(C 0 -C 3 )-alkylene-het, then het is azepine, azetidine, aziridine, azirine, 1,4-diazapane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 
   R 1  and R3 with the atoms to which they are bonded form azocane, azocane-2-one, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or   R 1 —N—R 2 —V form azepine, azetidine, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   V is
 2) phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R14, or 
 3) acridinyl, 8-aza-bicyclo[3.2.1]oct-3-yl, azaindole (1H-pyrrolopyridine), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 1,4-diazepane, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl, tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, 1λ6-thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, each of which is mono-, di- or trisubstituted independently of one another by R14; 
   M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R3 as 25) is —(C 0 -C 3 )-alkylene-O—CH 2 —(C 1 -C 3 )-perfluoroalkylene-CH 2 —O—(C 0 -C 3 )-allyl;   
     two —OR19 residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R13;
 R11 and R12 together with the nitrogen atom to which they are bonded may form azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; 
 R15 and R16 are independently of one another hydrogen, or —(C 1 -C 6 )-alkyl, or together with the carbon atom to which they are bonded form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R 10 ; and 
 R17 is —(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-OH, —(C 1 -C 6 )-alkyl-O—(C 1 -C 6 )-allyl, —(C 1 -C 6 )-alkyl-O—(C 1 -C 8 )-alkyl-(C 3 -C 8 )-cycloalkyl, or —(C 0 -C 6 )-alkyl-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by —OH, —O—(C 1 -C 4 )-alkyl or R 10 ; 
 
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       3 . The compound according to  claim 1 , wherein
 R 0  as
 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or 
 3) is azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, 2-furyl, 3-furyl; imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl; 2-pyrrolyl, 3-pyrrolyl, quinolinyl, quinazolinyl, quinoxalinyl, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl, each of which is additionally substituted by acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl, tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8; 
   R8 as 1) is fluorine, chlorine or bromine,
 provided R8 is at least one halogen, —C(O)—NH 2  or —O—(C 1 -C 8 )-allyl residue; 
   substructure D is pyridyl, pyridyl-N-oxide pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by ═O;   Q is a direct bond, —(C 0 -C 2 )-alkylene-C(O)—NR 10 —, —NR 10 —C(O)—NR 10 —, —NR 10 —C(O)—, —SO 2 — or —(C 1 -C 6 )-alkylene;   R 1  is hydrogen, —(C 1 -C 4 )-allyl, wherein the alkyl is unsubstituted or substituted one to three times by R13, —(C 1 -C 3 )-alkylene-C(O)—NH—R 0 , —(C 1 -C 3 )-alkylene-C(O)—O—R15, —(C 1 -C 3 )-perfluoroalkylene, —(C 1 -C 3 )-alkylene-S(O)—(C 1 -C 4 )-alkyl, —(C 1 -C 3 )-alkylene-S(O) 2 —(C 1 -C 3 )-alkyl, —(C 1 -C 3 )-alkylene-S(O) 2 —N(R 4′ )—R 5′ , —(C 1 -C 3 )-alkylene-O—(C 1 -C 4 )-alkyl, —(C 0 -C 3 )-alkylene-(C 3 -C 8 )-cycloalkyl, or —(C 0 -C 3 )-alkylene-het, wherein the het is azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or   R 1 —N—R 2 —V form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-di- or trisubstituted independently of one another by R14;   V is
 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 
 3) azaindole (1H-pyrrolopyridine), azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; 
   M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R3 is
 1) hydrogen, 
 2) halogen, 
 3) —(C 1 -C 4 )-allyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 4) —(C 1 -C 3 )-perfluoroalkyl, 
 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 6) —(C 0 -C 4 )-alkylene-O—R19, 
 8) —CN, 
 9) —SO s —R 11 , wherein s is 1 or 2, 
 10) —SO t —N(R 11 )—R 12 , wherein t is 1 or 2, 
 11) —(C 0 -C 4 )-alkylene-C(O)—R 11 , 
 12) —(C 0 -C 4 )-allylene-C(O)—O—R 11 , 
 13) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 12 , 
 14) —(C 0 -C 4 )-allylene-N(R 11 )—R 12 , 
 15) —NR 10 —SO 2 —R 10 , 
 17) —(C 0 -C 2 )-alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—(C 1 -C 4 )-alkyl, 
 18) —C(O)—O—C(R15,R16)-O—C(O)—R17, 
 19) —(C 0 -C 2 )-alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—O—(C 1 -C 6 )-alkyl, 
 20) —C(O)—O—C(R15,R16)-O—C(O)—O—R17, 
 21) —(C 0 -C 4 )-alkylene-(C 6 -C 14 )-aryl, wherein aryl is as defined above and is mono-, di- or trisubstituted independently of one another by R13, 
 22) —(C 0 -C 4 )-alkylene-(C 4 -C 15 )-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 23) —(C 0 -C 4 )-alkylene-(C 3 -C 8 )-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 24) —(C 0 -C 4 )-allylene-het, wherein the het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 25) —(C 0 -C 3 )-allylene-O—CH 2 —CF 2 —CH 2 —O—(C 0 -C 3 )-alkyl, —(C 0 -C 3 )-alkylene-O—CH 2 —CF 2 —CF 2 —CH 2 —O—(C 0 -C 3 )-allyl, or —(C 0 -C 3 )-alkylene-O—CH 2 —(C 1 -C 3 )-perfluoroalkylene-CH 2 —OH, 
 26) —SO w —N(R 11 )—R 13 , wherein w is 1 or 2, 
 27) —(C 0 -C 4 )-allylene-C(O)—N(R 11 )—R 13 , 
 28) —(C 0 -C 4 )-allylene-N(R 11 )—R 13 , or 
 29) a residue selected from the group consisting of 
   
     
       
         
         
             
             
         
       
     
     wherein Me is methyl, and two —OR19 residues and adjacent atoms through which they are attached form together with the atoms which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, which is substituted one, two, three or four times by R13;
 R11 and R12 are independently of one another identical or different and are
 1) hydrogen, 
 2) —(C 1 -C 6 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 3) —(C 0 -C 6 )-alkyl-(C 6 -C 14 )-aryl, wherein the alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R13, 
 4) —O—R 17 , or 
 5) —(C 0 -C 6 )-alkyl-(C 4 -C 15 )-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or 
 
 R11 and R12 together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; 
 R13 is fluorine, chlorine, bromine, iodine, —NO 2 , —CN, ═O, —OH, —CF 3 , —C(O)—O—R 10 , —C(O)—N(R 10 )—R 20 , —N(R 10 )—R 20 , —(C 0 -C 3 )-allylene-O—R 10 , —Si—(CH 3 ) 3 , —N(R 10 )—S(O) 2 —R 10 , —S—R 10 , —SO 2 —R 10 , —S(O) 2 —N(R 10 )—R 20 , —C(O)—R 10 , —(C 1 -C 8 )-allyl, —(C 1 -C 8 )-alkoxy, phenyl, phenyloxy-, —O—CF 3 , —(C 1 -C 3 )-perfluoroalkyl, —(C 0 -C 4 )-allyl-C(O)—O—C(R15,R16)-O—C(O)—R17, —(C 1 -C 4 )-alkoxy-phenyl, —(C 0 -C 4 )-alkyl-C(O)—O—C(R15,R16)-O—C(O)—O—R17, —O—R15, —NH—C(O)—NH—R 10 , —NH—C(O)—O—R 10 , or a residue selected from the group consisting of 
 
     
       
         
         
             
             
         
       
     
     wherein Me is methyl;
 R15 and R16 are independently of one another hydrogen, —(C 1 -C 6 )-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R 10 ; and 
 R17 is —(C 1 -C 6 )-allyl, —(C 1 -C 6 )-alkyl-OH, —(C 1 -C 6 )-alkyl-O—(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-O—(C 1 -C 8 )-alkyl-(C 3 -C 8 )-cycloalkyl, or —(C 1 -C 6 )-alkyl-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by —OH, —O—(C 1 -C 4 )-alkyl or R 10 ; 
 
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       4 . The compound according  claim 1 , wherein
 R0 as
 1) is phenyl, wherein phenyl is mono-, di- or trisubstituted independently of one another by R8, or 
 3) is pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl is pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,
 and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8; 
 
   R8 is
 1) F, Cl, Br or I, 
 4) —C(O)—NH 2 , 
 9) —(C 1 -C 4 )-alkyl, wherein the allyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, —OH or methoxy, or 
 10) —O—(C 1 -C 4 )-allyl, wherein the allyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy, provided that R8 is at least one halogen, —C(O)—NH 2  or —O—(C 1 -C 8 )-alkyl; 
   substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by ═O;   Q is a direct bond, —C(O)—, —SO 2 — or —(C 1 -C 6 )-alkylene, —(C 0 -C 2 )-alkylene-C(O)—NR 10 —;   R 1  is hydrogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 3 )-alkylene-C(O)—NH—R 0 , —(C 1 -C 3 )-perfluoroalkylene, —(C 1 -C 3 )-alkylene-C(O)—O—R 15 , —(C 1 -C 3 )-alkylene-S(O) 2 —(C 1 -C 3 )-alkyl or —(C 1 -C 3 )-alkylene-S(O) 2 —N(R 4′ )—R 5′ , wherein R 4′  and R 5′  independently of one another are hydrogen atom or —(C 1 -C 4 )-alkyl,   R 2  is a direct bond or —(C 1 -C 2 )-alkylene, or   R 1 —N—R 2 —V form azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R14 is fluorine, chlorine, —OH, ═O, —(C 1 -C 8 )-alkyl, —C(O)—OH, —CN, —NH 2 , —C(O)—O—(C 1 -C 4 )-alkyl, —C(O)—NH—(C 1 -C 8 )-allyl, —C(O)—N—[(C 1 -C 8 )-alkyl] 2 , —C(O)—NH 2  or —N(R 18 )—R 21 , wherein R 18  and R 21  are independently from each other hydrogen, —(C 1 -C 3 )-perfluoroalkyl or —(C 1 -C 4 )-alkyl;   V is
 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 
 3) azaindole (1H-pyrrolopyridine), aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine, piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, oxazole, isoxazole, 2-isoxazoline, isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, isothiazole, isothiazoline, isothiazolidine, 1,2-oxathiolan, thiodiazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; 
   G is a direct bond, —(CH 2 ) m —, or —(CH 2 ) m —NR 10 —;   m is zero, 1, 2, 3 or 4;   M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R3 is
 1) hydrogen, 
 2) halogen, 
 3) —(C 1 -C 4 )-allyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 4) —(C 1 -C 3 )-perfluoroalkyl, 
 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 6) —(C 0 -C 4 )-alkylene-O—R19, 
 8) —CN, 
 8) —NR 10 —SO 2 —R 10 , 
 9) —SO s —R 11 , wherein s is 1 or 2, 
 10) —SO t —N(R 11 )—R 12 , wherein t is 1 or 2, 
 11) —(C 0 -C 4 )-alkylene-C(O)—R 11 , 
 12) —(C 0 -C 4 )-alkylene-C(O)—O—R 11 , 
 13) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 12 , 
 14) —(C 0 -C 4 )-alkylene-N(R 11 )—R 12 , 
 17) —(C 0 -C 2 )alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—(C 1 -C 4 )-alkyl, 
 18) —C(O)—O—C(R15,R16)-O—C(O)—R17, 
 19) —(C 0 -C 2 )alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—O—(C 1 -C 6 )-allyl, 
 20) —C(O)—O—C(R15,R16)-O—C(O)—O—R17, 
 25) —(C 0 -C 3 )-alkylene-O—CH 2 —CF 2 —CH 2 —O—(C 0 -C 3 )-alkyl, —(C 0 -C 3 )-alkylene-O—CH 2 —CF 2 —CF 2 —CH 2 —O—(C 0 -C 3 )-allyl, or —(C 0 -C 3 )-allylene-O—CH 2 —(C 1 -C 3 )-perfluoroalkylene-CH 2 —OH, 
 26) —SO w —N(R 11 )—R 13 , wherein w is 1 or 2, 
 27) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 13 , 
 28) —(C 0 -C 4 )-alkylene-N(R 11 )—R 13 , or 
 29) a residue selected from the group consisting of 
   
     
       
         
         
             
             
         
       
       wherein Me is methyl; 
       two —OR19 residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R13; 
       R 11  and R 12  together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; 
       R13 is fluorine, chlorine, —NO 2 , —CN, ═O, —OH, —CF 3 , —C(O)—O—R 10 , —C(O)—N(R 10 )—R 20 , —N(R 10 )—R 20 , —(C 0 -C 3 )-alkylene-O—R 10 , —Si—(CH 3 ) 3 , —N(R 10 )—S(O) 2 —R 10 , —S—R 10 , —SO 2 —R 10 , —S(O) 2 —N(R 10 )—R 20 , —C(O)—R 10 , —(C 1 -C 8 )-allyl, —(C 1 -C 8 )-alkoxy, phenyl, phenyloxy-, —O—CF 3 , —(C 1 -C 3 )-perfluoroalkyl, —NH—C(O)—NH—R 10 , —(C 0 -C 4 )-alkyl-C(O)—O—C(R15,R16)-O—C(O)—R17, —(C 1 -C 4 )-alkoxy-phenyl, —(C 0 -C 4 )-alkyl-C(O)—O—C(R15,R16)-O—C(O)—O—R17, —O—R15, —NH—C(O)—O—R 10 , or a residue selected from the group consisting of 
     
     
       
         
         
             
             
         
       
       wherein Me is methyl; 
       R15 and R16 are independently of one another hydrogen, —(C 1 -C 6 )-allyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R 10 ; and 
       R17 is —(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-OH, —(C 1 -C 6 )-alkyl-O—(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-O—(C 1 -C 8 )-alkyl-(C 3 -C 8 )-cycloalkyl, or —(C 0 -C 6 )-alkyl-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by —OH, —O—(C 1 -C 4 )-alkyl or R 10 ; 
     
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       5 . The compound according to  claim 1 , wherein
 R0 is 1) phenyl, wherein the phenyl is mono-, di- or trisubstituted independently of one another by R8,   2) indolyl, isoindolyl, benzofuranyl, benzothiophenyl, 1,3-benzodioxolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromanyl, isochromanyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridyl, purinyl or pteridinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,   3) pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;   R8 is
 1) F, Cl, Br, or I, 
 4) —C(O)—NH 2 , 
 9) —(C 1 -C 4 )-allyl, wherein the allyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, —OH or methoxy, or 
 10) —O—(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy, provided that R8 is at least one halogen, —C(O)—NH 2  or —O—(C 1 -C 8 )-alkyl residue; 
   substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by ═O;   Q is a direct bond, —C(O)—, —SO 2 —, —(C 1 -C 6 )-alkylene or —(C 0 -C 2 )-alkylene-C(O)—NR 10 —;   R 1  is hydrogen or —(C 1 -C 2 )-alkyl,   R 2  is a direct bond or —(C 1 -C 2 )-alkylene, or   R 1 —N—R 2 —V form piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R14 is fluorine, chlorine, ═O, —(C 1 -C 4 )-alkyl or —NH 2 ;   V is
 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 
 3) azaindolyl (1H-pyrrolopyridyl), azetidine, azepine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazirine, 1,3-dioxolane, dioxazole, furan, imidazole, isoquinoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline, isoxazolidine, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, 1,2-oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, piperazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline, quinoline, tetrazine, tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; 
   G is a direct bond, —(CH 2 ) m —, or —(CH 2 ) m —NR 10 —;   m is zero, 1, 2, 3 or 4;   M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R3 is
 1) hydrogen, 
 2) halogen, 
 3) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 4) —(C 1 -C 3 )-perfluoroalkyl, 
 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 6) —(C 0 -C 4 )-alkylene-O—R19, 
 8) —CN, 
 9) —SO s —R 11 , wherein s is 1 or 2, 
 10) —SO t —N(R 11 )—R 12 , wherein t is 1 or 2, 
 11) —(C 0 -C 4 )-alkylene-C(O)—R 11 , 
 12) —(C 0 -C 4 )-alkylene-C(O)—O—R 11 , 
 13) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 12 , 
 14) —(C 0 -C 4 )-alkylene-N(R 11 )—R 12 , 
 15) —NR 10 —SO 2 —R 10 , 
 17) —(C 0 -C 2 )alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—(C 1 -C 4 )-allyl, 
 18) —C(O)—O—C(R15,R16)-O—C(O)—R17, 
 19) —(C 0 -C 2 )allylene-C(O)—O—(C 2 -C 4 )-allylene-O—C(O)—O—(C 1 -C 6 )-alkyl, 
 20) —C(O)—O—C(R15,R16)-O—C(O)—O—R17, or 
 29) a residue selected from the group consisting of 
   
     
       
         
         
             
             
         
       
       wherein Me is methyl; 
       R19 is
 a) hydrogen, 
 b) —(C 1 -C 4 )-alkyl, wherein the allyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 c) —CF 3 , or 
 d) —CHF 2 ; 
 
       R11 and R12 are independently of one another identical or different and are 
       1) hydrogen, 
       2) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
       3) —(C 0 -C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, 
       7) —O—R 17 , or 
       8) —(C 0 -C 6 )-alkyl-(C 4 -C 15 )-heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl is azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or 
       R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine; 
       R13 is fluorine, —CN, ═O, —OH, —CF 3 , —C(O)—O—R 10 , —C(O)—N(R 10 )—R 20 , —N(R 10 )—R 20 , —(C 3 -C 6 )-cycloalkyl, —(C 0 -C 3 )-alkylene-O—R 10 , —Si—(CH 3 ) 3 , —S—R 10 , —SO 2 —R 10 , —(C 1 -C 3 )-perfluoroalkyl, or a residue selected from the group consisting of 
     
     
       
         
         
             
             
         
       
        wherein Me is methyl; 
       R 10  and R 20  are independently of one another hydrogen, —(C 1 -C 4 )-alkyl or —(C 1 -C 3 )-perfluoroalkyl; 
       R 15  and R 16  are independently of one another hydrogen, —(C 1 -C 4 )-allyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R 10 , and 
       R17 is —(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-OH, —(C 1 -C 6 )-alkyl-O—(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-O—(C 1 -C 8 )-alkyl-(C 3 -C 8 )-cycloalkyl, or —(C 0 -C 6 )-alkyl-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by —OH, —O—(C 1 -C 4 )-alkyl or R 10 ; 
     
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       6 . The compound according to  claim 1 , wherein
 R0 is
 1) phenyl, wherein the phenyl is mono- or disubstituted independently of one another by R8, 
 2) pyridyl or benzothiophenyl, wherein the pyridyl and benzothiophenyl are unsubstituted or mono- or disubstituted independently of one another by R8, or 
 3) thienyl, thiadiazolyl, isoxazolyl or thiazolyl, each of which is substituted by thienyl, 2-thienyl or 3-thienyl, wherein the thienyl, 2-thienyl or 3-thienyl is unsubstituted or mono- or disubstituted independently of one another by R8; 
   R8 is F, Cl, Br, —OCH 3  or —C(O)—NH 2 ;   substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by ═O;   Q is a direct bond, —C(O)—, —SO 2 —, —CH 2 —C(O)—NH—, methylene or ethylene;   R 1  is hydrogen,   R 2  is a direct bond or methylene, or   R 1 —N—R 2 —V form azetidine, pyrrolidine, piperidine and piperazine;   R14 is fluorine, chlorine, ═O, methyl, ethyl or —NH 2 ;   V is
 2) phenyl, wherein the phenyl is unsubstituted or mono- or disubstituted independently of one another by R14 or 
 3) azaindolyl (1H-pyrrolopyridyl), azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, quinazoline, quinoline or tetrahydropyrane, each of which is unsubstituted or mono- or disubstituted independently of one another by R14; 
   G is a direct bond, —(CH 2 ) m —, or —(CH 2 ) m —NR 10 —;   m is zero, 1 or 2;   M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R3 is
 1) hydrogen, 
 2) F or Cl, 
 3) —(C 1 -C 4 )-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 4) —(C 1 -C 3 )-perfluoroalkyl, 
 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 6) —(C 0 -C 2 )-alkylene-O—R19, 
 8) —CN, 
 9) —SO s R 11 , wherein s is 1 or 2, 
 10) —SO t —N(R 11 )—R 12 , wherein t is 1 or 2, 
 11) —(C 0 -C 4 )-alkylene-C(O)—R 11 , 
 12) —(C 0 -C 4 )-allylene-C(O)—O—R 11 , 
 13) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 12 , 
 14) —(C 0 -C 4 )-alkylene-N(R 11 )—R 12 , 
 15) —NR 10 —SO 2 —R 10 , 
 17) —(C 0 -C 2 )alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—(C 1 -C 4 )-alkyl, 
 18) —C(O)—O—C(R15,R16)-O—C(O)—R17, 
 19) —(C 0 -C 2 )alkylene-C(O)—O—(C 2 -C 4 )-alkylene-O—C(O)—O—(C 1 -C 6 )-alkyl or 
 20) —C(O)—O—C(R15,R16)-O—C(O)—O—R17; 
   R19 is
 a) hydrogen, 
 b) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or 
 c) —CF 3 , or 
 d) —CHF 2 ; 
   R11 and R12 are independently of one another identical or different and are
 1) hydrogen, 
 2) —(C 1 -C 4 )-alkyl, wherein the allyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 3) —(C 0 -C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, 
 7) —O—R 17 , or 
 8) —(C 0 -C 6 )-alkyl-heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl is azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine, or 
   R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane piperazine, piperidine, pyrrolidine or thiomorpholine;   R 13  is fluorine, —CN, ═O, —OH, —CF 3 , —C(O)—O—R 10 , —C(O)—N(R 10 )—R 20 , —N(R 10 )—R 20 , —(C 3 -C 6 )-cycloalkyl, —(C 0 -C 3 )-alkylene-O—R 11 , —Si—(CH 3 ) 3 , —S—R 10 , —SO 2 —R 10 , or —(C 1 -C 3 )-perfluoroalkyl;   R 10  and R 20  are independently of one another hydrogen, —(C 1 -C 4 )-alkyl or —(C 1 -C 3 )-perfluoroalkyl;   R 15  and R 16  are independently of one another hydrogen, —(C 1 -C 4 )-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R 10 ; and   R 17  is —(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-alkyl-OH, —(C 1 -C 6 )-alkyl-O—(C 1 -C 6 )-alkyl, —(C 1 -C 6 )-allyl-O—(C 1 -C 8 )-alkyl-(C 3 -C 8 )-cycloalkyl, or —(C 0 -C 6 )-allyl-(C 3 -C 8 )-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by —OH, —O—(C 1 -C 4 )-alkyl or R 10 ;   
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       7 . The compound according to  claim 1 , wherein
 R0 is
 2) pyridyl or benzothiophenyl, wherein the pyridyl and benzothiophenyl are unsubstituted or mono- or disubstituted independently of one another by R8, or 
 3) thienyl, thiadiazolyl, isoxazolyl and thiazolyl, each of which is substituted by thienyl, 2-thienyl and 3-thienyl, wherein the thienyl, 2-thienyl or 3-thienyl is unsubstituted or mono- or disubstituted independently of one another by R8; 
   R8 is F, Cl, Br, —OCH 3  or —C(O)—NH 2 ;   substructure D is pyridyl and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by ═O;   Q is —CH 2 —C(O)—NH— or methylene;   R 1  is hydrogen atom;   R 2  is a direct bond;   R 14  is fluorine, chlorine, ═O, methyl, ethyl or —NH 2 ;   V is piperidine, wherein the piperidine is unsubstituted or mono- or disubstituted independently of one another by R14;   G is a direct bond;   M is a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;   R3 is
 1) hydrogen, 
 2) fluorine, or chlorine, 
 3) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, 
 6) —(C 0 -C 2 )-allylene-O—R19, 
 12) —(C 0 -C 4 )-allylene-C(O)—O—R 11  or 
 13) —(C 0 -C 4 )-alkylene-C(O)—N(R 11 )—R 12 ; 
   R19 is
 a) hydrogen or 
 b) —(C 1 -C 4 )-alkyl, wherein the allyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; 
   R11 and R12 are independently of one another identical or different and are
 1) hydrogen or 
 2) —(C 1 -C 4 )-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or 
   R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane piperazine, piperidine, pyrrolidine or thiomorpholine;   R13 is fluorine, ═O, —OH, —CF 3 , —C(O)—O—R 10 , —C(O)—N(R 10 )—R 20 , —N(R 10 )—R 20 , or —(C 0 -C 3 )-allylene-O—R 10 ; and   R 10  and R 20  are independently of one another hydrogen, —(C 1 -C 4 )-allyl or —(C 1 -C 3 )-perfluoroalkyl;   
     or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       8 . A process for the preparation of a compound according to  claim 1 , which comprises condensing a compound of formula 29 with a compound of the formula HR 8′  to give a compound of formula 30 and converting the compound of the formula 30 into a compound of the formula I, 
     
       
         
         
             
             
         
       
     
     wherein the residue R 8′  has the donation of —N(R 1 )—R 2 —V-G-M as indicated  claim 1 , but where in R 8′  functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in —N(R 1 )—R 2 —V-G-M, and where the residue R 54  denotes the group -Q-R o  or can denote a group which is subsequently transformed into the group -Q-R o , and where the group —C(O)—R 53  can be a carboxylic acid group or derivatives thereof, and where the groups R 3a  in the formulae 29 and 30 have the corresponding definitions of R 3  in formula I as defined in  claim 1  or functional groups in them can also be present in protected form or in the form of precursor groups. 
   
   
       9 . A pharmaceutical composition, comprising at least one compound according to  claim 1  or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
   
   
       10 . A method for influencing blood coagulation in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to  claim 1 , or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       11 . A method for inhibiting influencing blood fibrinolysis in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to  claim 1 , or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof. 
   
   
       12 . A method for treating abnormal thrombus formation, acute myocardial infarction, cardiovascular disorders, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulatopathy occurring in vascular systems during septic shock, viral infections or cancer, or reducing an inflammatory response, fibrinolysis, or treatment of coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting disorder, deep vein or proximal vein thrombosis, which can occur following surgery, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to  claim 1 , or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.